Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia

Study Status

Open to Enrollment

Study Description

This study is evaluating two different doses and two different dosing schedules of plerixafor with decitabine in people with Acute Myeloid Leukemia (AML) age 60 and older.

Acute Myeloid Leukemia is a very difficult disease to treat, especially in those who are older than 60. Standard treatment--a combination of chemotherapy drugs-is intensive and not feasible for many older patients with the disease. Also, AML in older patients is less likely to be successfully treated with chemotherapy even for those patients who can tolerate the treatment. This research study is being conducted to determine how safe and effective the combination of decitabine and plerixafor is in treating AML.

The hypothesis of this study is that combining plerixafor, an inhibitor of stromal cell derived factor, with decitabine, a DNA methyltransferase inhibitor, as induction and postremission therapy for older patients with AML will improve treatment outcomes via mobilization of leukemia stem cells and alteration of the pharmacodynamics of decitabine.

Decitabine has been shown to be an effective treatment option for some older patients with AML. Plerixafor is used to mobilize stem cells for lymphoma and multiple myeloma patients who are having a stem cell transplant. The researchers believe plerixafor may be able to mobilize leukemia cells from their hiding places inside the bone marrow and make them more accessible to decitabine treatment.

Disease Status and/or Stage

Acute Myeloid Leukemia (AML)

Sponsor

Weill Cornell Medical College

Key Eligibility

  • Men and women ≥ age 60
  • Diagnosed with Acute Myeloid Leukemia (AML)
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Gail Roboz, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page